Melatonin-induced osteogenesis with methanol-annealed silk materials
Source abstract
Abstract
Melatonin, a hormone produced in the pineal gland, has been investigated for bone repair, remodeling, osteoporosis, as well as osseointegration of the implants. In this study, different concentrations of melatonin (0–2000-µM) were embedded into silk films annealed by methanol or water. Then, their capacity to differentiate human mesenchymal stem cells into osteoblasts was investigated for bone tissue regeneration. While methanol-annealed silk films have ~55% crystallinity, room-temperature water-annealed silk films have ~30% crystallinity by depending upon their different β-sheet contents. Melatonin-loaded silk films exhibited an initial burst release followed by a continuous release for up to 5 days, and the β-sheet content of silk films did not affect the release behavior of melatonin, an amphiphilic molecule. Moreover, human mesenchymal stem cells exhibited an increase in osteogenic markers such as alkaline phosphatase activity, osteocalcin, and runt-related transcription factor 2 expressions on the melatonin-loaded methanol-annealed silk films in both proliferation and osteogenic media. The bioactivity of the melatonin-modified silk films was further confirmed by the enhanced mineralization compared to silk films alone. This study demonstrated the feasibility of developing melatonin-loaded silk materials and the positive effect of releasing melatonin at micromolar concentrations on osteogenic differentiation of human mesenchymal stem cells cultured especially in osteogenic medium.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Silk-based biomaterials and applications · Protein Hydrolysis and Bioactive Peptides · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, Hacettepe University, Ankara, Turkey
Department of Biomedical Engineering, Tufts University, Medford, MA, USA
References (31)
Show source-provided references
1. 10.3109/02652048.2015.111590110.3109/02652048.2015.1115901 ↗
2. 10.1080/21691401.2017.138974710.1080/21691401.2017.1389747 ↗
3. 10.3390/ijms14051006310.3390/ijms140510063 ↗
4. 10.1097/00007632-200105010-0000610.1097/00007632-200105010-00006 ↗
5. 10.1074/jbc.274.31.2204110.1074/jbc.274.31.22041 ↗
6. 10.1111/jpi.1217710.1111/jpi.12177 ↗
7. 10.1111/j.1600-079X.2006.00410.x10.1111/j.1600-079X.2006.00410.x ↗
8. 10.1111/j.1600-079X.1999.tb00603.x10.1111/j.1600-079X.1999.tb00603.x ↗
9. 10.1111/j.1600-079X.2006.00318.x10.1111/j.1600-079X.2006.00318.x ↗
10. 10.1111/j.1600-079X.2010.00784.x10.1111/j.1600-079X.2010.00784.x ↗
11. 10.1111/j.1600-079X.2010.00803.x10.1111/j.1600-079X.2010.00803.x ↗
12. 10.1111/j.1600-079X.2012.01016.x10.1111/j.1600-079X.2012.01016.x ↗
13. 10.1111/j.1600-079X.2012.00989.x10.1111/j.1600-079X.2012.00989.x ↗
14. 10.1016/j.progpolymsci.2007.05.01310.1016/j.progpolymsci.2007.05.013 ↗
15. 10.1021/bm701235f10.1021/bm701235f ↗
16. 10.1177/088391151350353810.1177/0883911513503538 ↗
17. 10.1038/nprot.2011.37910.1038/nprot.2011.379 ↗
18. 10.1021/bm200062a10.1021/bm200062a ↗
19. 10.1002/mabi.20090029410.1002/mabi.200900294 ↗
20. 10.1016/j.jconrel.2005.12.00910.1016/j.jconrel.2005.12.009 ↗
21. 10.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-710.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-7 ↗
22. 10.1002/jbm.a.3018610.1002/jbm.a.30186 ↗
23. 10.1016/j.biomaterials.2012.08.00410.1016/j.biomaterials.2012.08.004 ↗
24. Zwirska-Korczala K · J Physiol Pharmacol · 2005 · 56 · 91
25. Cal vo-Guirado JL · J Osseointegration · 2015 · 7 · 23
26. 10.1111/jpi.1202310.1111/jpi.12023 ↗
27. 10.1016/j.bone.2013.02.02110.1016/j.bone.2013.02.021 ↗
28. 10.1007/s10856-005-4715-610.1007/s10856-005-4715-6 ↗
29. 10.1177/088391151139941010.1177/0883911511399410 ↗
30. 10.1097/MAT.0b013e31802deb2d10.1097/MAT.0b013e31802deb2d ↗
31. 10.1111/jpi.1211610.1111/jpi.12116 ↗